tert-butyl 7-nitro-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate | 1171126-83-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: tert-butyl 7-nitro-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate
• 英文别名: tert-Butyl 7-nitro-2,3-dihydro-4H-1,4-benzoxazine-4-carboxylate；tert-butyl 7-nitro-2,3-dihydro-1,4-benzoxazine-4-carboxylate
• CAS: 1171126-83-2
• 化学式: C₁₃H₁₆N₂O₅
• 分子量: 280.28
• InChiKey: WGYJWGCUEGQLNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  84.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 7-nitro-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate 在 palladium 10% on activated carbon 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 生成 tert-butyl 7-(3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thioureido)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate
  参考文献：
  名称：

  Structure–activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

  摘要：

  In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-A beta and A beta plaques in cells and transgenic animals. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.04.005
• 作为产物：
  描述：

  7-硝基-2H-1,4-苯并噁嗪-3-酮 在 硼烷四氢呋喃络合物 、 碳酸氢钠 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.5h， 生成 tert-butyl 7-nitro-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate
  参考文献：
  名称：

  Structure–activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

  摘要：

  In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-A beta and A beta plaques in cells and transgenic animals. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.04.005

文献信息

• Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications
  作者：Nathaniel J. Henning、Andrew G. Manford、Jessica N. Spradlin、Scott M. Brittain、Erika Zhang、Jeffrey M. McKenna、John A. Tallarico、Markus Schirle、Michael Rape、Daniel K. Nomura

  DOI：10.1021/jacs.1c03980

  日期：2022.1.19

  recruiter, have arisen as a powerful therapeutic modality for targeted protein degradation (TPD). Despite the popularity of TPD approaches in drug discovery, only a small number of E3 ligase recruiters are available for the >600 E3 ligases that exist in human cells. Here, we have discovered a cysteine-reactive covalent ligand, EN106, that targets FEM1B, an E3 ligase recently discovered as the critical component

  蛋白水解靶向嵌合体 (PROTAC) 是一种异双功能化合物，由与 E3 连接酶募集剂连接的蛋白靶向配体组成，已成为靶向蛋白降解 (TPD) 的强大治疗方式。尽管 TPD 方法在药物发现中很受欢迎，但只有少数 E3 连接酶招募人员可用于人类细胞中存在的 >600 E3 连接酶。在这里，我们发现了一种半胱氨酸反应性共价配体 EN106，其靶向 FEM1B，这是一种最近发现的 E3 连接酶，是细胞对还原应激反应的关键组成部分。通过针对 FEM1B 中的 C186，EN106 破坏了对 FEM1B 关键还原应力基质 FNIP1 的识别。我们通过证明将 EN106 连接到 BET 溴结构域抑制剂 JQ1 或激酶抑制剂达沙替尼的 PROTAC 分别导致 BRD4 和 BCR-ABL 的降解，进一步确定 EN106 可用作 TPD 应用中 FEM1B 的共价招募剂。我们的研究展示了一种针对天然 E3 连
• [EN] FEM1B PROTEIN BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS SE LIANT À LA PROTÉINE FEM1B ET UTILISATIONS ASSOCIÉES
  申请人：UNIV CALIFORNIA

  公开号：WO2021183431A1

  公开（公告）日：2021-09-16

  Disclosed herein, inter alia, are compounds for binding FEMIB protein and uses thereof. In an aspect, provided herein is a pharmaceutical composition including a compound as described herein and a pharmaceutically acceptable excipient.

  本文披露了用于结合FEMIB蛋白的化合物及其用途。在一个方面，本文提供了一种包括本文描述的化合物和药用可接受的赋形剂的药物组合物。
• IMIDAZOLE CARBONYL COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20140073622A1

  公开（公告）日：2014-03-13

  To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.

  为了开发一种具有新型作用机制的抗生素，本发明者寻找具有以下特点的化合物：细胞毒性较弱、在水中溶解度高、能够抑制DNA旋转酶GyrB和拓扑异构酶IV ParE亚基，以及具有足够的抗菌活性。结果，本发明者通过发现本发明的一般式（1）所表示的化合物、其药理学可接受的盐和前药具有理想的特性来完成了本发明。本发明提供了一种药物组合物（特别是用于预防或治疗传染病的组合物），其包括由公式（1）所表示的化合物、其药理学可接受的盐或前药作为活性成分。
• Imidazole carbonyl compound
  申请人：Soneda Tsuyoshi

  公开号：US08536197B2

  公开（公告）日：2013-09-17

  An antibiotic compound having a novel mechanism of action, weak cytotoxicity, high solubility in water, effective in inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and having antibacterial activity.

  一种抗生素化合物，具有新颖的作用机制，细胞毒性较弱，水溶性高，能有效抑制DNA旋转酶GyrB和拓扑异构酶IV ParE亚基，并具有抗菌活性。